U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Pituitary carcinoma

MedGen UID:
91096
•Concept ID:
C0346300
•
Neoplastic Process
Synonyms: Cancer of Pituitary; Cancer of the Pituitary; Cancer, Pituitary; Cancers, Pituitary; Carcinoma, Pituitary; Carcinomas, Pituitary; Pituitary Cancer; Pituitary Cancers; Pituitary Carcinoma; Pituitary Carcinomas
SNOMED CT: Pituitary carcinoma (128665000); Pituitary carcinoma (254955001)
Modes of inheritance:
Unknown inheritance
MedGen UID:
989040
•Concept ID:
CN307042
•
Finding
Source: Orphanet
Hereditary clinical entity whose mode of inheritance is unknown.
See: This record
Unknown inheritance (Orphanet)
 
HPO: HP:0011763
Monarch Initiative: MONDO:0017582
Orphanet: ORPHA300385

Definition

A pituitary tumor with subarachnoid, brain, or systemic metastasis. The diagnosis of a pituitary carcinoma requires evidence of metastatic disease, either outside the central nervous system (CNS) or as separate noncontiguous foci within the CNS. [from HPO]

Professional guidelines

PubMed

Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain.
Lamas C, Cámara R, Fajardo C, Remon-Ruiz P, Biagetti B, Guerrero-Pérez F, Araujo-Castro M, Mora M, Hanzu F, Iglesias P, García-Centeno R, Soto A
Front Endocrinol (Lausanne) 2023;14:1204206. Epub 2023 Aug 31 doi: 10.3389/fendo.2023.1204206. PMID: 37720528Free PMC Article
The treatment of aggressive prolactinomas with everolimus.
Lin AL, Geer EB, Lala N, Page-Wilson G, Magge R, Young RJ, Tabar V
Pituitary 2023 Aug;26(4):474-481. Epub 2023 Jul 10 doi: 10.1007/s11102-023-01340-5. PMID: 37428396Free PMC Article
European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas.
Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, Trouillas J, Dekkers OM; European Society of Endocrinology
Eur J Endocrinol 2018 Jan;178(1):G1-G24. Epub 2017 Oct 18 doi: 10.1530/EJE-17-0796. PMID: 29046323

Recent clinical studies

Etiology

Immunotherapy for endocrine tumours: a clinician's perspective.
Angelousi A, Tzoulis P, Tsoli M, Chatzellis E, Koumarianou A, Kaltsas G
Endocr Relat Cancer 2024 Apr 1;31(4) Epub 2024 Feb 12 doi: 10.1530/ERC-23-0296. PMID: 38235757
Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain.
Lamas C, Cámara R, Fajardo C, Remon-Ruiz P, Biagetti B, Guerrero-Pérez F, Araujo-Castro M, Mora M, Hanzu F, Iglesias P, García-Centeno R, Soto A
Front Endocrinol (Lausanne) 2023;14:1204206. Epub 2023 Aug 31 doi: 10.3389/fendo.2023.1204206. PMID: 37720528Free PMC Article
The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal.
Villa C, Baussart B, Assié G, Raverot G, Roncaroli F
Endocr Relat Cancer 2023 Aug 1;30(8) Epub 2023 Jun 22 doi: 10.1530/ERC-23-0021. PMID: 37068095
Overview of the 2022 WHO Classification of Pituitary Tumors.
Asa SL, Mete O, Perry A, Osamura RY
Endocr Pathol 2022 Mar;33(1):6-26. Epub 2022 Mar 15 doi: 10.1007/s12022-022-09703-7. PMID: 35291028
Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma).
Lenders N, McCormack A
Pituitary 2018 Apr;21(2):217-229. doi: 10.1007/s11102-017-0857-z. PMID: 29299820

Diagnosis

The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal.
Villa C, Baussart B, Assié G, Raverot G, Roncaroli F
Endocr Relat Cancer 2023 Aug 1;30(8) Epub 2023 Jun 22 doi: 10.1530/ERC-23-0021. PMID: 37068095
Overview of the 2022 WHO Classification of Pituitary Tumors.
Asa SL, Mete O, Perry A, Osamura RY
Endocr Pathol 2022 Mar;33(1):6-26. Epub 2022 Mar 15 doi: 10.1007/s12022-022-09703-7. PMID: 35291028
European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas.
Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, Trouillas J, Dekkers OM; European Society of Endocrinology
Eur J Endocrinol 2018 Jan;178(1):G1-G24. Epub 2017 Oct 18 doi: 10.1530/EJE-17-0796. PMID: 29046323
Pituitary carcinoma.
Sansur CA, Oldfield EH
Semin Oncol 2010 Dec;37(6):591-3. doi: 10.1053/j.seminoncol.2010.10.012. PMID: 21167378
Pituitary carcinoma: diagnosis and treatment.
Lopes MB, Scheithauer BW, Schiff D
Endocrine 2005 Oct;28(1):115-21. doi: 10.1385/ENDO:28:1:115. PMID: 16311418

Therapy

Temozolomide in aggressive pituitary tumours and pituitary carcinomas.
McCormack A
Best Pract Res Clin Endocrinol Metab 2022 Dec;36(6):101713. Epub 2022 Oct 13 doi: 10.1016/j.beem.2022.101713. PMID: 36274026
Pituitary carcinoma as a rare cause of liver metastases successfully treated with temozolomide.
Stelmachowska-Banaś M, Maksymowicz M, Kolasińska-Ćwikła A, Zieliński G, Korbonits M, Zgliczyński W
Pol Arch Intern Med 2022 Mar 30;132(3) Epub 2021 Dec 22 doi: 10.20452/pamw.16178. PMID: 34935323
Aggressive pituitary tumours and pituitary carcinomas.
Raverot G, Ilie MD, Lasolle H, Amodru V, Trouillas J, Castinetti F, Brue T
Nat Rev Endocrinol 2021 Nov;17(11):671-684. Epub 2021 Sep 7 doi: 10.1038/s41574-021-00550-w. PMID: 34493834
Is there a role for early chemotherapy in the management of pituitary adenomas?
Lin AL, Sum MW, DeAngelis LM
Neuro Oncol 2016 Oct;18(10):1350-6. Epub 2016 Apr 21 doi: 10.1093/neuonc/now059. PMID: 27106409Free PMC Article
Pituitary carcinoma: diagnosis and treatment.
Lopes MB, Scheithauer BW, Schiff D
Endocrine 2005 Oct;28(1):115-21. doi: 10.1385/ENDO:28:1:115. PMID: 16311418

Prognosis

Therapeutic targeting of the pituitary tumor microenvironment.
Ilie MD, De Alcubierre D, Carretti AL, Jouanneau E, Raverot G
Pharmacol Ther 2023 Oct;250:108506. Epub 2023 Aug 9 doi: 10.1016/j.pharmthera.2023.108506. PMID: 37562699
The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal.
Villa C, Baussart B, Assié G, Raverot G, Roncaroli F
Endocr Relat Cancer 2023 Aug 1;30(8) Epub 2023 Jun 22 doi: 10.1530/ERC-23-0021. PMID: 37068095
Aggressive corticotroph tumors and carcinomas.
Lasolle H, Vasiljevic A, Jouanneau E, Ilie MD, Raverot G
J Neuroendocrinol 2022 Aug;34(8):e13169. Epub 2022 Aug 18 doi: 10.1111/jne.13169. PMID: 35979732Free PMC Article
Aggressive pituitary tumours and pituitary carcinomas.
Raverot G, Ilie MD, Lasolle H, Amodru V, Trouillas J, Castinetti F, Brue T
Nat Rev Endocrinol 2021 Nov;17(11):671-684. Epub 2021 Sep 7 doi: 10.1038/s41574-021-00550-w. PMID: 34493834
Pituitary carcinomas.
Colao A, Ochoa AS, Auriemma RS, Faggiano A, Pivonello R, Lombardi G
Front Horm Res 2010;38:94-108. Epub 2010 Jul 5 doi: 10.1159/000318499. PMID: 20616500

Clinical prediction guides

Therapeutic targeting of the pituitary tumor microenvironment.
Ilie MD, De Alcubierre D, Carretti AL, Jouanneau E, Raverot G
Pharmacol Ther 2023 Oct;250:108506. Epub 2023 Aug 9 doi: 10.1016/j.pharmthera.2023.108506. PMID: 37562699
The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal.
Villa C, Baussart B, Assié G, Raverot G, Roncaroli F
Endocr Relat Cancer 2023 Aug 1;30(8) Epub 2023 Jun 22 doi: 10.1530/ERC-23-0021. PMID: 37068095
Aggressive pituitary tumours and pituitary carcinomas.
Raverot G, Ilie MD, Lasolle H, Amodru V, Trouillas J, Castinetti F, Brue T
Nat Rev Endocrinol 2021 Nov;17(11):671-684. Epub 2021 Sep 7 doi: 10.1038/s41574-021-00550-w. PMID: 34493834
Aggressive Pituitary Adenomas and Carcinomas.
Ilie MD, Jouanneau E, Raverot G
Endocrinol Metab Clin North Am 2020 Sep;49(3):505-515. Epub 2020 Jul 8 doi: 10.1016/j.ecl.2020.05.008. PMID: 32741485
Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma).
Lenders N, McCormack A
Pituitary 2018 Apr;21(2):217-229. doi: 10.1007/s11102-017-0857-z. PMID: 29299820

Recent systematic reviews

Knowing when to discontinue Temozolomide therapy in responding aggressive pituitary tumors and carcinomas: a systematic review and Padua (Italy) case series.
Padovan M, Cerretti G, Caccese M, Barbot M, Bergo E, Occhi G, Scaroni C, Lombardi G, Ceccato F
Expert Rev Endocrinol Metab 2023 Mar;18(2):181-198. Epub 2023 Mar 6 doi: 10.1080/17446651.2023.2185221. PMID: 36876325
Outcome and prognostic factors for pituitary carcinomas: lessons from a systematic review.
Raymond P, Raverot G, Ilie MD
Endocr Relat Cancer 2023 May 1;30(5) Epub 2023 Mar 31 doi: 10.1530/ERC-22-0338. PMID: 36852675
Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review.
Ilie MD, Vasiljevic A, Jouanneau E, Raverot G
Endocr Relat Cancer 2022 May 27;29(7):415-426. doi: 10.1530/ERC-22-0037. PMID: 35521777
Immune-checkpoint inhibitors in pituitary malignancies.
Di Nunno V, Franceschi E, Tosoni A, Gatto L, Maggio I, Lodi R, Bartolini S, Brandes AA
Anticancer Drugs 2022 Jan 1;33(1):e28-e35. doi: 10.1097/CAD.0000000000001157. PMID: 34348358
Genetic aspects of pituitary carcinoma: A systematic review.
Yang Z, Zhang T, Gao H
Medicine (Baltimore) 2016 Nov;95(47):e5268. doi: 10.1097/MD.0000000000005268. PMID: 27893664Free PMC Article

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Reviews

    Related information

    • ClinVar
      Related medical variations
    • MeSH
      Related Medical Subject Headings
    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...